New Lab Will Make Drug Discovery More Efficient, says Biofocus

By Dan Stanton

- Last updated on GMT

Related tags Drug discovery Contract research organization Pharmacology

Punting on the Cam? Biofocus set to move into new lab facility
Punting on the Cam? Biofocus set to move into new lab facility
Biofocus says it is literally bringing its scientists closer together to aid its drug discovery services with a new 60,000 square foot facility in Cambridge, UK.

The Contract Research Organisation (CRO), a subsidiary of the Galapagos Group, currently occupies four buildings at the Chesterford Research Park but announced today it has signed a pre-let agreement for a new laboratory facility which will bring its drug discovery groups together.

Dr. Chris Newton, Biofocus’ Managing Director, told the firm’s current buildings are relatively elderly and the “question of efficiency”​ was the drive behind the move to the new facility.

A modern facility increases energy efficiency, he said, creating “added synergies and increased cost-savings which are very important for CROs.”

Furthermore, Newton continued: “Biofocus lays claims to self-sufficient drug discovery services across all therapeutic areas and if our scientists are very close together we are efficient. Discovering drugs is all about talking to each other and sharing ideas.”

Biofocus’s Cambridge site does not deal any UK clients, Newton said, but rather had a number of customers from the US, Europe and Japan.

Punting on the Cam

The facility is set to be up and running with operations transferred to the Park’s ‘Robinson Building’ within the next two years. Chesterford is currently home to both Pfizer and Illumina, amongst other pharma and life science companies.

“This is great news for Chesterford Research Park and also for the South Cambridge life sciences cluster,”​ said Martin Sylvester, from Churchmanor Estates, one of the joint developers at the site.   “Aside from the AstraZeneca deal, this is the largest pre-let in the Cambridge area since 2011 and represents a very significant investment in the region’s economy.”

AstraZeneca announced in March it was building a £330m ($513m) facility in Cambridge​, as a new strategic R&D centre and global headquarters. However, it also announced it would be ceasing its R&D operations at its lab in Cheshire and relocating staff to the new site where possible.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more